Coherus Insists Demand Is ‘Pent Up’ For On-Body Pegfilgrastim Biosimilar

As Company Plots ‘Very Careful Review Over Time’ For Udenyca PFS

 
• By Dean Rudge

California-Based Coherus BioSciences delved further into its plans and expectations for its proposed proprietary pegfilgrastim on-body device, as it also detailed continued pricing challenges for the pre-filled syringe formulation.

Amgen logo sign hanging on the office building in Rotkreuz, Switzerland
"Taking share from Onpro will be a source of growth" • Source: Alamy

More from Biosimilars

More from Products